June 10, 2021
Sumitomo Dainippon Pharma has entered into a collaborative research and development agreement, with an additional option agreement, for Nippon Chemiphar’s investigational novel antidepressant/anxiolytic drug candidate NC-2800, the two companies said on June 9. NC-2800 is a novel emotion modulating agent...read more